Name | Number of supported studies | Average coverage | |
---|---|---|---|
type I pneumocyte | 7 studies | 23% ± 4% | |
adipocyte | 6 studies | 19% ± 4% | |
astrocyte | 5 studies | 28% ± 7% | |
epithelial cell of proximal tubule | 4 studies | 20% ± 5% | |
fibroblast | 4 studies | 23% ± 4% | |
epithelial cell | 3 studies | 30% ± 8% | |
type II pneumocyte | 3 studies | 20% ± 4% | |
GABAergic neuron | 3 studies | 24% ± 8% | |
glutamatergic neuron | 3 studies | 38% ± 9% |
Insufficient scRNA-seq data for expression of MTARC2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 7992.46 | 226 / 226 | 100% | 98.70 | 404 / 406 |
prostate | 100% | 1645.49 | 244 / 245 | 100% | 33.30 | 501 / 502 |
kidney | 100% | 3542.28 | 89 / 89 | 99% | 50.05 | 890 / 901 |
thymus | 100% | 4029.51 | 653 / 653 | 98% | 33.34 | 591 / 605 |
pancreas | 100% | 1339.43 | 328 / 328 | 97% | 23.71 | 173 / 178 |
breast | 100% | 1730.98 | 459 / 459 | 92% | 26.92 | 1033 / 1118 |
adrenal gland | 100% | 1789.10 | 258 / 258 | 92% | 20.45 | 212 / 230 |
lung | 100% | 2902.70 | 578 / 578 | 91% | 17.67 | 1055 / 1155 |
stomach | 100% | 1868.25 | 359 / 359 | 89% | 14.97 | 255 / 286 |
intestine | 100% | 1778.77 | 966 / 966 | 89% | 14.97 | 468 / 527 |
uterus | 97% | 872.26 | 165 / 170 | 83% | 14.32 | 381 / 459 |
bladder | 100% | 1296.52 | 21 / 21 | 80% | 11.06 | 401 / 504 |
esophagus | 97% | 1458.89 | 1403 / 1445 | 73% | 11.65 | 134 / 183 |
brain | 83% | 815.06 | 2205 / 2642 | 72% | 16.67 | 509 / 705 |
ovary | 100% | 2145.94 | 180 / 180 | 40% | 4.49 | 173 / 430 |
skin | 74% | 409.47 | 1333 / 1809 | 49% | 8.33 | 229 / 472 |
adipose | 100% | 1901.92 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2003.10 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 1205.68 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 10.22 | 1 / 1 |
heart | 99% | 1543.37 | 855 / 861 | 0% | 0 | 0 / 0 |
muscle | 97% | 795.16 | 780 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 73% | 8.69 | 33 / 45 |
eye | 0% | 0 | 0 / 0 | 60% | 9.56 | 48 / 80 |
lymph node | 0% | 0 | 0 / 0 | 31% | 3.33 | 9 / 29 |
peripheral blood | 9% | 91.03 | 85 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0070458 | Biological process | cellular detoxification of nitrogen compound |
GO_0042126 | Biological process | nitrate metabolic process |
GO_0006809 | Biological process | nitric oxide biosynthetic process |
GO_0051410 | Biological process | detoxification of nitrogen compound |
GO_0005741 | Cellular component | mitochondrial outer membrane |
GO_0005777 | Cellular component | peroxisome |
GO_0005739 | Cellular component | mitochondrion |
GO_0016661 | Molecular function | oxidoreductase activity, acting on other nitrogenous compounds as donors |
GO_0098809 | Molecular function | nitrite reductase activity |
GO_0043546 | Molecular function | molybdopterin cofactor binding |
GO_0030170 | Molecular function | pyridoxal phosphate binding |
GO_0030151 | Molecular function | molybdenum ion binding |
GO_0008940 | Molecular function | nitrate reductase activity |
Gene name | MTARC2 |
Protein name | Mitochondrial amidoxime reducing component 2 Mitochondrial amidoxime reducing component 2 (mARC2) (EC 1.7.-.-) (Molybdenum cofactor sulfurase C-terminal domain-containing protein 2) (MOSC domain-containing protein 2) (Moco sulfurase C-terminal domain-containing protein 2) |
Synonyms | MARC2 MOSC2 |
Description | FUNCTION: Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles . As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability . May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis . Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transfer from NADH to cytochrome b5 reductase then to cytochrome b5, the ultimate electron donor that primes the active site for substrate reduction . . |
Accessions | ENST00000425560.1 X1WI34 ENST00000469583.1 ENST00000366913.8 [Q969Z3-1] Q969Z3 ENST00000359316.6 [Q969Z3-2] F6V6Z1 |